Baxter International Inc. ($BAX) Stock Forecast: Down 5.2% Today

What is Baxter International Inc.?

Baxter International Inc (BAX) is a global healthcare company that focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. The company's stock had a bearish movement today, closing 4.86% lower at $19.38.

Why is Baxter International Inc. going down?

BAX stock is down 5.2% on Mar 3, 2026 16:41

• A reduction in stake by CI Investments Inc. in BlackRock might have prompted investors to reallocate their funds, affecting the market sentiment.
• Smith+Nephew's innovative technologies displayed at the AAOS Annual Meeting could have diverted investor attention away from Baxter International, resulting in decreased demand for BAX shares.
• An expansion by Intuitive in Europe may have shifted focus in the overall healthcare market, especially in the medical devices and biotechnology sectors, potentially diverting interest from Baxter International.
• The projected growth in the hemodialysis therapy market suggests a potential change in investor preferences towards companies in the renal care sector, potentially overshadowing Baxter International's performance for the day.

BAX Price Chart

BAX Technical Analysis

BAX News

BlackRock $BLK Shares Sold by CI Investments Inc.

CI Investments Inc. recently reduced its stake in BlackRock by 22.4% in the third quarter, selling over 25,000 shares. Meanwhile, other institutional investors have either increased or initiated positions in BlackRock. The article also covers BlackRock's dividend increase, recent insider trading activity, key news impacts, and analyst ratings.

https://www.marketbeat.com/instant-alerts/filing-blackrock-blk-shares-sold-by-ci-investments-inc-2026-03-03/

Smith+Nephew to feature leading rotator cuff repair

Smith+Nephew will showcase its rotator cuff repair (RCR) portfolio, including the new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant, at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting. The company aims to improve RCR outcomes in a market segment that still experiences high structural failure rates with traditional surgical techniques. These technologies emphasize both biomechanical repair and biological augmentation, with the REGENETEN implant supported by a strong recommendation from the AAOS for its effectiveness in reducing re-tear rates and improving patient outcomes.

https://www.globenewswire.com/news-release/2026/03/02/3247745/0/en/smith-nephew-to-feature-leading-rotator-cuff-repair-portfolio-including-new-tendon-seam-repair-system-and-regeneten-bioinductive-implant-at-aaos-2026.html

Baxter International Inc (BAX) Trading Down 4.86% on Mar 2

Baxter International Inc (BAX) shares dropped 4.86% on March 2, with the stock closing at $19.38. This price is significantly below its 52-week high, though still above its 52-week low. Wall Street analysts currently recommend a "Hold" status for BAX, with an average target price suggesting an 11.74% upside, while GuruFocus estimates a fair value implying an 87.72% upside.

https://www.gurufocus.com/news/8669627/baxter-international-inc-bax-trading-down-486-on-mar-2

Intuitive expands direct operations for da Vinci, Ion distro in Europe

Intuitive (Nasdaq: ISRG) has completed the acquisition of its da Vinci and Ion distribution business in Europe from Ab Medica, Abex, and Excelencia Robótica. This move formally expands Intuitive's direct operations in Europe, specifically in Italy, Spain, Portugal, Malta, San Marino, and associated territories, to enhance customer support and broaden access to minimally invasive care. The acquisition integrates approximately 250 employees and aims to improve patient outcomes, experience, and lower healthcare costs in these regions.

https://www.massdevice.com/intuitive-expands-direct-operations-for-da-vinci-ion-distro-in-europe/

Hemodialysis Therapy Market to Reach US$ 19.81 Billion by 2031

The Hemodialysis Therapy Market is projected to grow from US$ 13.03 billion in 2023 to US$ 19.81 billion by 2031, exhibiting a CAGR of 5%. This growth is primarily fueled by the increasing prevalence of chronic kidney disease, an aging population, and technological advancements in dialysis treatments. North America currently leads the market with a 40% share, driven by a well-established healthcare infrastructure and high renal disease prevalence.

https://www.openpr.com/news/4409437/hemodialysis-therapy-market-to-reach-us-19-81-billion-by-2031

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.8% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.3% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 5.3% Today

Welltower Inc. ($WELL) Stock Forecast: Down 0.9% Today

Tapestry Inc. ($TPR) Stock Forecast: Down 5.0% Today

Booking Holdings Inc. ($BKNG) Stock Forecast: Up 7.8% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

Corning Incorporated ($GLW) Stock Forecast: Down 8.0% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 6.5% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 5.3% Today

Baxter International Inc. Price History

13.01.2026 - BAX Stock was up 5.2%

• Q4 2025 earnings call transcript revealed detailed discussions on financial performance and future outlook, suggesting positive prospects that resonated well with investors.
• Despite a net loss reported in the 2025 10-K report, Baxter's focus on streamlining operations through divestitures and core segments may have boosted investor confidence in the company's long-term strategy.
• A downgrade to a hold rating following weak Q4 results and a disappointing FY 2026 guide could have initially affected investor sentiment. However, the subsequent appointment of Michael R. McDonnell to the Board of Directors and strategic efforts for a turnaround likely instilled optimism, leading to the stock's bullish movement today.

03.02.2026 - BAX Stock was down 5.2%

• A reduction in stake by CI Investments Inc. in BlackRock might have prompted investors to reallocate their funds, affecting the market sentiment.
• Smith+Nephew's innovative technologies displayed at the AAOS Annual Meeting could have diverted investor attention away from Baxter International, resulting in decreased demand for BAX shares.
• An expansion by Intuitive in Europe may have shifted focus in the overall healthcare market, especially in the medical devices and biotechnology sectors, potentially diverting interest from Baxter International.
• The projected growth in the hemodialysis therapy market suggests a potential change in investor preferences towards companies in the renal care sector, potentially overshadowing Baxter International's performance for the day.

04.01.2026 - BAX Stock was up 5.2%

• BAX encountered challenges in Q4, such as disappointing Q3 results, a dividend reduction, and delays in IV fluid volume normalization and Novum pump shipments, resulting in underperformance.
• Growth projections in the outpatient oncology infusion market could have a beneficial impact on BAX, given its role in fostering innovation in this area.
• Hospitals opting to phase out desflurane over environmental concerns could indirectly assist BAX, as the transition to eco-friendly alternatives may boost the company's image.
• The announcement of Avidity Biosciences' share distribution and Axogen's recent equity offerings might have positively influenced investor sentiment, contributing to the bullish momentum in BAX's stock.

12.01.2026 - BAX Stock was down 12.7%

• Baxter International Inc. reported a Q4 earnings miss and provided a weak outlook for 2026, leading to a sharp decline in its stock price.
• Despite revenue exceeding estimates, the company's adjusted EPS fell short, and its projected earnings for the upcoming year were below expectations, causing concern among investors.
• The substantial GAAP loss and cautious guidance for 2026 highlighted potential profitability and operational challenges for the company, contributing to the bearish market movement.
• The stock tumbled as much as 14.63% in pre-market trading following the disappointing financial results and outlook, reflecting investors' apprehensions about Baxter's performance in the near future.

12.01.2026 - BAX Stock was down 15.0%

• Baxter International Inc. (BAX) saw its stock price plummet by 13.3% to 14.63% in pre-market trading following the earnings announcement.
• The decline in BAX's stock price can be linked to the fourth-quarter earnings falling below analyst expectations, notably with an adjusted EPS of $0.44 missing projections.
• Furthermore, the company's conservative 2026 forecast, with anticipated flat to 1% sales growth and adjusted EPS below consensus estimates, added to investor worries about Baxter's future.
• Despite introducing a new operating model aimed at streamlining its operations and enhancing performance, Baxter's stock experienced a significant drop, overshadowing the efforts to mitigate the impact of the disappointing earnings and outlook.

18.01.2026 - BAX Stock was up 7.5%

• Baxter International (BAX) has experienced a strong bullish movement, with its stock rising by 4.80%.
• The positive market reaction could be attributed to investors potentially viewing the recent losses and challenges as temporary setbacks, leading to increased confidence in the company's future prospects.
• Despite concerns about earnings volatility and debt, the market seems to be responding positively to Baxter International's recent performance, outperforming its competitors on a strong trading day.
• The bullish movement might also be influenced by the overall positive sentiment in the market, as indicated by modest gains in the S&P 500 and Dow Jones Industrial Average.

18.01.2026 - BAX Stock was up 6.6%

• Baxter International (BAX) saw a strong bullish movement despite financial challenges and negative sentiment from analysts.
• The positive market movement could be attributed to investors potentially viewing the company's low valuation metrics, such as the P/S ratio, as compensatory for concerns about earnings volatility and high debt levels.
• The market might be reacting favorably to Baxter International's resilience in the face of financial hurdles, possibly seeing potential for a turnaround in its earnings recovery narrative.
• Despite the obstacles pointed out by analysts, the bullish trend in Baxter International's stock price suggests that investors are optimistic about the company's future prospects and its ability to navigate through the current challenges.

21.10.2025 - BAX Stock was up 5.2%

• The multiple class action lawsuits against Baxter International might have initially caused uncertainty and a dip in the stock price.
• However, investors might have regained confidence in the company due to positive developments or reassurances from Baxter International's management.
• This bullish movement could indicate that investors believe the impact of the lawsuits on the company's financials and reputation might be manageable.
• It's possible that some investors see an opportunity in the temporary dip caused by the lawsuits and are now buying the stock at a lower price, contributing to the bullish movement.

15.00.2026 - BAX Stock was up 5.2%

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

10.01.2026 - BAX Stock was up 5.3%

• The bullish movement in Baxter International Inc. (BAX) could be attributed to the positive news surrounding the company's commitment to respiratory health for patients, showcasing its dedication to improving patient care and quality of life.
• The downgrades from financial firms may have initially caused some uncertainty in the market, but the strong focus on innovative healthcare solutions and patient support likely reassured investors, leading to the bullish trend.
• The workforce reduction at a plant impacted by Hurricane Helene could have been perceived as a strategic move by Baxter to streamline operations and enhance efficiency, potentially positively impacting the company's bottom line and investor confidence.
• The overall positive sentiment towards Baxter International Inc. (BAX) amid its focus on healthcare innovation and patient support likely contributed to the bullish market movement despite some external challenges and analyst downgrades.

12.10.2025 - BAX Stock was up 5.1%

• Despite the pending class action lawsuits and reminders to shareholders, Baxter International Inc. saw a bullish trend, indicating that investors may have confidence in the company's ability to navigate through legal challenges.
• The market movement could be attributed to positive developments within the company that outweigh the legal uncertainties highlighted in recent discussions.
• Investors might be optimistic about Baxter International's future performance and potential growth prospects in the healthcare industry, leading to increased buying activity and driving the stock price higher.

31.09.2025 - BAX Stock was down 5.4%

• Today's downward trend in Baxter International Inc. (BAX) stock may be linked to the following factors:
• A pending securities fraud class action lawsuit by The Gross Law Firm has caused apprehension among investors, resulting in a decrease in confidence and a sell-off of shares.
• Baxter has revised its annual outlook and lowered its 2025 guidance on multiple occasions, which might have negatively impacted investor sentiment, with the stock hitting a 52-week low after the latest adjustment in guidance.
• Despite Baxter's Q3 earnings surpassing expectations, the stock dropped due to a sales shortfall and a downward revision in the 2025 EPS forecast, suggesting potential challenges in revenue generation ahead.
• Ongoing investigations and shareholder alerts by legal firms like Faruqi & Faruqi, LLP and Bernstein Liebhard LLP have contributed to the overall uncertainty surrounding the company, potentially influencing the bearish market movement.